Negative trial of nifedipine in depression

Kramer, Mark S.; Caputo, Kevin; DiJohnson, Celeste; Maldonado, L Carlos; Mirow, Arvin; Sheves, Patricia; Sholevar, Farhad

doi:10.1016/0006-3223(88)90242-9

Cited by 7 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Considering only reports with a sample size of three or more subjects, we could identify 27 studies published so far examining the efficacy of calcium-channel blockers for mood disorders as summarized in Tables IIa and IIb [Caillard and Masse, 1982;Giannini et al, 1984Giannini et al, , 1985Giannini et al, , 1987Goldstein, 1984;Brotman et al, 1986;Dose et al, 1986;Dubovsky et al, 1986Dubovsky et al, , 2001Barton and Gitlin, 1987;Dinan et al, 1988;Kramer et al, 1988;Mathis et al, 1988;Hoschl and Kozeny, 1989;Brunet et al, 1990;De Beaurepaire, 1992;Garza-Trevino et al, 1992;Goodnick, 1993;Pazzaglia et al, 1993;Lenzi et al, 1995;Walden et al, 1995;Walton et al, 1996;Janicak et al, 1998;Pazzaglia et al, 1998;Silverstone and Birkett, 2000;Wisner et al, 2002;Taragano et al, 2005]. Of these, 14 were single or double-blind controlled studies (eight with a crossover design), 7 were open trials, and 6 were case series.…”

Section: Clinical Investigationmentioning

confidence: 99%

L‐type calcium channels and psychiatric disorders: A brief review

Casamassima

Hay

Benedetti

et al. 2010

American J of Med Genetics Pt B

116

View full text Add to dashboard Cite

Emerging evidence from genome-wide association studies (GWAS) support the association of polymorphisms in the alpha 1C subunit of the L-type voltage-gated calcium channel gene (CACNA1C) with bipolar disorder. These studies extend a rich prior literature implicating dysfunction of L-type calcium channels (LTCCs) in the pathophysiology of neuropsychiatric disorders. Moreover, calcium channel blockers reduce Ca(2+) flux by binding to the α1 subunit of the LTCC and are used extensively for treating hypertension, preventing angina, cardiac arrhythmias and stroke. Calcium channel blockers have also been studied clinically in psychiatric conditions such as mood disorders and substance abuse/dependence, yielding conflicting results. In this review, we begin with a summary of LTCC pharmacology. For each category of disorder, this article then provides a review of animal and human data. In particular, we extensively focus on animal models of depression and clinical trials in mood disorders and substance abuse/dependence. Through examining rationale and study design of published clinical trials, we provide some of the possible reasons why we still do not have definitive evidence of efficacy of calcium-channel antagonists for mood disorders. Refinement of genetic results and target phenotypes, enrollment of adequate sample sizes in clinical trials and progress in physiologic and pharmacologic studies to synthesize tissue and isoform specific calcium channel antagonists, are all future challenges of research in this promising field. © 2010 Wiley-Liss, Inc.

show abstract

Section: Clinical Investigationmentioning

confidence: 99%

L‐type calcium channels and psychiatric disorders: A brief review

Casamassima

Hay

Benedetti

et al. 2010

American J of Med Genetics Pt B

116

View full text Add to dashboard Cite

show abstract

“…In open and controlled studies, nimodipine has seemed to be particularly useful in the treatment and prevention of both manic and depressive episodes 103 . However, nifedipine was not effective for depression in a small study, 104 and an animal study suggested that nifedipine interfered with the effects of antidepressants and electroconvulsive shock on the density of corticosteroid receptors 105 …”

Section: Studies Of Calcium Antagonists In Bipolar Disordermentioning

confidence: 99%

“…46 In open and controlled studies, nimodipine has seemed to be particularly useful in the treatment and prevention of both manic and depressive episodes. 103 However, nifedipine was not effective for depression in a small study, 104 and an animal study suggested that nifedipine interfered with the effects of antidepressants and electroconvulsive shock on the density of corticosteroid receptors. 105 The 2 negative mania trials of verapamil that were discussed previously 81,82 led to conclusions by some reviewers that this CCB is ineffective in bipolar disorder, a generalization that is usually not applied to contradictory experience with other medications with proposed antimanic and mood stabilizing effects, such as some anticonvulsants and atypical antipsychotic drugs.…”

Section: Studies Of Calcium Antagonists In Bipolar Disordermentioning

confidence: 99%

Calcium Channel Antagonists for Mood Disorders

Dubovsky

Marshall

2022

J Clin Psychopharmacol

View full text Add to dashboard Cite

Purpose: Development of new thymoleptic medications has primarily centered on anticonvulsants and antipsychotic drugs. Based on our studies of intracellular calcium ion signaling in mood disorders, we were interested in the use of novel medications that act on this mechanism of neuronal activation as potential mood stabilizers. Method:We reviewed the dynamics of the calcium second messenger system and the international body of data demonstrating increased baseline and stimulated intracellular calcium levels in peripheral cells of patients with bipolar mood disorders. We then examined studies of the effect of established mood stabilizers on intracellular calcium ion levels and on mechanisms of mobilization of this second messenger. After summarizing studies of calcium channel blocking agents, whose primary action is to attenuate hyperactive intracellular calcium signaling, we considered clinical experience with this class of medications and the potential for further research.Findings: Established mood stabilizers normalize increased intracellular calcium ion levels in bipolar disorder patients. Most case series and controlled studies suggest an antimanic and possibly mood stabilizing effect of the calcium channel blocking medications verapamil and nimodipine, with fewer data on isradipine. A relatively low risk of teratogenicity and lack of cognitive adverse effects or weight gain suggest possible applications in pregnancy and in patients for whom these are considerations.Implications: Medications that antagonize hyperactive intracellular signaling warrant more interest than they have received in psychiatry. Further experience will clarify the applications of these medications alone and in combination with more established mood stabilizers.

show abstract

“…Einer der ersten Berichte einer antimanischen Wirkung von Verapamil, getestet in einem Crossoverdesign, stammt von Dubovsky et al (1982). Weitere Einzelfallbeobachtungen mit Verapamil berichteten Patterson (1987) bei Manie, Gitlin u. Weiss (1984) sowie Solomon u. Williamson (1986) 240-360 Caillard 198530 -10 Eckmann 1985Kramer et al 1988Brunet et al 1990Manna et al 1991Pazzaglia et al 1993Post et al 1993Höschl u. Kozeny 1989Dubovsky et al 1986Giannini et al 1987 Barton u. (Pazzaglia et al 1993).…”

Section: Klinische Studien Mit Kalziumantagonisten Bei Affektiven Stöunclassified

Bedeutung kalziumantagonistischer Effekte für die medikamentöse Therapie affektiver Störungen^*

Langosch

Walden²

1998

Fortschr Neurol Psychiatr

View full text Add to dashboard Cite

Disturbances of intra- and extracellular calcium levels are often reported during the course of affective disorders. In this review calcium antagonistic properties of drugs used in the treatment of affective disorders are discussed. The effects of calcium channel blockers in animal models of depression and in clinical trials are compared to established treatment strategies. Knowledge on changes in calcium homoeostasis during the treatment of affective disorders may increase the scope of therapeutic options.

show abstract

Negative trial of nifedipine in depression

Cited by 7 publications

References 7 publications

L‐type calcium channels and psychiatric disorders: A brief review

L‐type calcium channels and psychiatric disorders: A brief review

Calcium Channel Antagonists for Mood Disorders

Bedeutung kalziumantagonistischer Effekte für die medikamentöse Therapie affektiver Störungen^*

Contact Info

Product

Resources

About

Negative trial of nifedipine in depression

Cited by 7 publications

References 7 publications

L‐type calcium channels and psychiatric disorders: A brief review

L‐type calcium channels and psychiatric disorders: A brief review

Calcium Channel Antagonists for Mood Disorders

Bedeutung kalziumantagonistischer Effekte für die medikamentöse Therapie affektiver Störungen*

Contact Info

Product

Resources

About

Bedeutung kalziumantagonistischer Effekte für die medikamentöse Therapie affektiver Störungen^*